Clinical Scorecard: Analysis of Breakthrough COVID-19 Cases in Hematological Disorder Patients Undergoing Pre-Exposure Prophylaxis with Tixagevimab-Cilgavimab: A Retrospective Study Conducted in Japan

At a Glance

Key Highlights

• 7.5% incidence of breakthrough COVID-19 among 257 hematological disorder patients receiving 300 mg each of Tix/Cil.
• No COVID-19-related mortality observed; majority of breakthrough cases were mild to moderate in severity.
• Breakthrough infection incidence consistent with international data despite variant-related neutralization challenges.

Guideline-Based Recommendations

Diagnosis

• COVID-19 severity classified per US NIH treatment guidelines.
• Diagnosis based on antigen testing and clinical presentation.

Management

• Use of antiviral agents such as nirmatrelvir/ritonavir or remdesivir for mild to moderate COVID-19.
• Oxygen therapy and immunosuppressive agents like dexamethasone for severe cases.

Monitoring & Follow-up

• Close follow-up post-Tix/Cil administration, especially within first 100 days.
• Monitor for breakthrough infection symptoms and hospital admission necessity.

Risks

• Reduced neutralization efficacy of Tix/Cil against Omicron variants may increase breakthrough risk.
• Immunosuppressed status and recent therapies (e.g., anti-CD20 antibodies, CAR-T) may influence infection risk.

Patient & Prescribing Data

257 patients with hematological disorders, including those post-hematopoietic stem cell transplantation and receiving B cell-depleting therapies.

300 mg dosing of Tix/Cil used as pre-exposure prophylaxis; breakthrough infections occurred mostly within 25 days post-administration.

Clinical Best Practices

• Administer Tix/Cil pre-exposure prophylaxis to high-risk hematological patients per national guidance.
• Maintain vaccination where possible, noting suboptimal humoral response in this population.
• Employ antiviral treatments promptly upon breakthrough infection to prevent progression.
• Hospitalize patients with moderate to severe COVID-19 for close monitoring and supportive care.

References

• WHO COVID-19 Timeline
• US NIH COVID-19 Treatment Guidelines
• FDA Update on Tixagevimab/Cilgavimab Dosing
• Japanese Ministry of Health, Labour and Welfare Guidance on Tix/Cil